|View printer-friendly version|
|Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research|
“The launch of Charles River’s NCG model provides a significant
opportunity to assist our clients in the development of life-saving,
translational therapies,” said Dr.
The NCG model was co-developed by the
This model complements Charles River’s extensive portfolio of oncology
products and services, including studies in human xenograft, syngeneic,
and humanized immunotherapy research models, flow cytometry, and IVIS® imaging
Charles River is introducing the NCG model to its North American customer base at the 2017 AACR Annual Meeting, which highlights the best cancer science and medicine from institutions all over the world. A full schedule of Charles River’s activities during the 2017 AACR Annual Meeting is available on their website, and reprints of each poster are available in Charles River’s booth (#1421) during the conference. Additionally, experts are available to discuss the NCG model, as well as their capabilities and expertise in oncology research. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.